XPS™ to Germany

The University Hospital in Essen, Germany has decided to acquire the Xvivo
Perfusion system, XPS™. This is the second XPS™ to a German hospital. It is
estimated that delivery and installation of the XPS™ will take place in January
2016.
The XPS™ is the only system on the market for Ex Vivo Lung Perfusion (EVLP) that
is approved on all major markets, including US approval by the FDA. The XPS™
system gives the user the flexibility to perform evaluation of lungs for
transplantation using a standardized and simplified procedure. The XPS™ has
achieved good clinical results when used at leading clinics in the USA and
Europe. In Europe, four clinics will have the XPS-system, whereof two clinics in
Germany. In total, XVIVO Perfusion will have installed 21 XPS™ globally and the
company notes a continued high interest for the XPS™ in Europe and the US.

“We are very pleased that the clinic in Essen, which is one of the most
important clinics in Germany, now starts to use XPS™ to facilitate EVLP," says
Magnus Nilsson, CEO of XVIVO Perfusion.

December 23, 2015
Gothenburg
XVIVO Perfusion AB (publ)
For further information please contact:
Christoffer Rosenblad, CFO, +1 720 616 2101,
christoffer.rosenblad@xvivoperfusion.com
For further information on XVIVO Perfusion’s business, please refer to the
company’s website, www.xvivoperfusion.com

The information was submitted for publication on December 23, 2015 at 8:30 a.m.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.
________________________________________________________________________________
_ 
_____________________________________

XVIVO Perfusion AB is a medical technology company which develops solutions and
systems for assessing and preserving organs outside the body and for selecting
usable organs and maintaining them in optimal condition pending transplantation.
The company is headquartered in Gothenburg, Sweden, and has one office in the
USA. The XVIVO share is listed on NASDAQ OMX First North and has the ticker
symbol XVIVO. More information can be found on the website
www.xvivoperfusion.com. The Certified Adviser is Redeye, www.redeye.se.
________________________________________________________________________________
_ 
_____________________________________

XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity
number 556561-0424.
Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: info@xvivoperfusion.com. Website: www.xvivoperfusion.com